NP 001 - Novabio Therapeutics
Alternative Names: NP-001 - Novabio TherapeuticsLatest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Novabio Therapeutics
- Class Gene therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple system atrophy
Most Recent Events
- 01 Nov 2024 Phase-I clinical trials in Alzheimer's disease in China (Intrathecal) (NCT06671236)
- 01 Nov 2024 Phase-I clinical trials in Amyotrophic lateral sclerosis in China (Intrathecal) (NCT06671236)
- 01 Nov 2024 Phase-I clinical trials in Multiple system atrophy in China (Intrathecal) (NCT06671236)